and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen???s ability to maintain sufficient capital; and other risks described in the Company???s filings with the Securities and Exchange Commission.